Bristol-Myers Squibb Company (BMY) :The total money flow, which is calculated as the dollar value of composite uptick minus downtick trades was negative ($62.03 million) and the uptick to downtick ratio was 0.53. The transaction value on upticks was $68.89 million and on downticks, the transaction value was $130.93 million. In block trades, the transaction value of inflow done during uptick was $15.61 million. The transaction value of block trades during downticks was $74.52 million. The uptick to downtick block trade ratio was 0.21. The money flow was negative ($58.92 million), indicating the traders were booking profit on the price strength. Bristol-Myers Squibb Company (BMY) rose $0.81 at $76.2, during intraday Tuesday , a rise of 1.07% over the previous days close.
The company Insiders own 0.24% of Bristol-Myers Squibb Company shares according to the proxy statements. In the past twelve weeks, the net percent change held by company insiders has changed by -16.24% . Institutional Investors own 74.66% of Bristol-Myers Squibb Company shares. During last six month period, the net percent change held by insiders has seen a change of -14.27%. In an insider trading activity, Andreotti Lamberto, Director of BRISTOL MYERS SQUIBB CO, unloaded 23,200 shares at an average price of $72.31 on June 28, 2016. The total amount of the transaction was worth $1,677,592, according to the disclosed information with the Securities and Exchange Commission in a Form 4 filing.
Shares of Bristol-Myers Squibb Company rose by 3.28% in the last five trading days and 5.44% for the last 4 weeks. Bristol-Myers Squibb Company is up 14.61% in the last 3-month period. Year-to-Date the stock performance stands at 12.02%.
Bristol-Myers Squibb Company (NYSE:BMY): stock turned positive on Tuesday. Though the stock opened at $75.48, the bulls momentum made the stock top out at $76.55 level for the day. The stock recorded a low of $75.48 and closed the trading day at $76.2, in the green by 1.07%. The total traded volume for the day was 5,935,551. The stock had closed at $75.39 in the previous days trading.
Bristol-Myers Squibb Company (BMS) is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products across the world. The Companys products are sold to wholesalers, retail pharmacies, hospitals, government entities and the medical profession. The Company manufactures its products in the United States, Puerto Rico and in six foreign countries. The Company promotes the use of its products directly to healthcare professionals and providers, such as doctors, nurse practitioners, physician assistants, pharmacists, technologists, hospitals, Pharmacy Benefit Managers (PBMs) and Managed Care Organizations (MCOs). It also provides information about the use of its products to consumers in the United States through direct-to-consumer print, radio, television, and digital advertising and promotion. In addition, the Company holds rights to F001287, which is a preclinical, small-molecule IDO1-inhibitor.